As of press time, the three major indexes of Hong Kong stocks rose, the Hang Seng index rose 0.29% to 19420.07 points, with a turnover of 40.193 billion; the state-owned enterprises index rose 0.5% to 6660.16 points, with a turnover of 11.812 billion; and the red chip index rose 0.73% to 3724.71 points, with a turnover of 1.758 billion.

Bank shares rose generally, Standard Chartered Group and Bank of East Asia rose 2%, HSBC Holdings and Dah Sing Bank rose 1%, Bank of China Hong Kong and Hang Seng Bank followed suit.

CRO concept stocks plummeted, Pharmaceutical Biology fell more than 20% at one point, Caleb, Yao Ming Kant and Tiger Pharmaceuticals all fell more than 10%. Us President Joe Biden is preparing to sign an executive order to help the development of US biological manufacturing industry. Details of the executive order have not yet been made public, and according to people familiar with the matter, the draft order sets out a strategy to promote the development of domestic manufacturing in the United States, using biotechnology to create a range of products and materials such as new drugs, biofuels and food.

Apple's concept stock rose collectively, spurred by hot bookings for iPhone 14 and a surge in Apple's share price. Among them, BYD Electronics is up nearly 10%, Gao Wei Electronics is up more than 8%, and Shunyu is up more than 3%. Pre-sale data show that financial institutions such as JPMorgan Chase and Barclays all indicate that Apple's latest iPhone 14 Pro Max will become the best-selling mobile phone model, showing that it has a chance to surpass the old version.

Hot stocks

Zhou's Black Duck's share price continues to rise, now trading at HK $3.83, or 4.4%, with a total market capitalization of HK $9.13 billion. Anxin International reported that the company's reform measures were carried out in an orderly manner, the store expansion was good, and the epidemic did have an impact. However, from the rapid recovery after the epidemic, the company's products are still loved by consumers, and the company's profitability still has high room for growth in the future. Maintain a "buy" rating on the company's shares with a target price of HK $5.2

Yongtai Bio-B rose 157.14% to HK $9 at the beginning of the session, and its share price reached its highest level since the end of January this year. Public information shows that Yongtai Biological is an innovative high-tech enterprise specializing in the research and development and application of cellular immune technology products. It is also the first company to obtain clinical approval for CFDA therapeutic immune cell biological products. The company focuses on high-growth market segments. Compared with similar enterprises, the product has low cost and wide applicability, and two clinical approvals of adoptive cellular immunotherapy have been obtained.